Company: SHPH
Filing Date: 2025-03-05
Form Type: S-1/A
Source: 0001493152-25-009106
Chunk: 48

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-05
Form: S-1/A
Chunk 48
---
 voting and investment 
 power over the securities of the Company  held by the Master Fund and thus may be deemed to beneficially own the securities            
 of the Company held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own       
 the securities of the Company held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities   
 of the Company directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment      
 Management Agreement with Armistice Capital. Does not include 1,826,000 pre-funded warrants held by Armistice Capital,                 
 which pre-funded warrants may be exercised from time to time and are subject to a 9.99% ownership limitation, and warrants to purchase 
 2,885,246 shares of common stock, which warrants remain subject to exercise and are subject to a maximum 9.99% ownership limitation.   |

| 31 |

Change of Control

The Company is not aware of any arrangements which may at a subsequent date result in a change of control of the Company.

Securities authorized for issuance under equity compensation plans

2018 Equity Incentive Plan

Our 2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market value of the underlying shares as determined pursuant to the Plan, restricted stock awards, other stock- based awards, or any combination of the foregoing. The Plan is administered by the Company’s compensation committee or, alternatively, if there is no compensation committee, the Company’s board of directors. We have reserved 3,000,000 shares of our common stock for issuance under the Plan, of which 1,174,683 shares have been granted under the Plan as of the date of this registration statement and 244,439 remain subject to vesting.

The following table provides information as of December 31, 2024 about our equity compensation plans and arrangements, as adjusted for the February 28, 2025 accelerated vesting of grants to resigning board members.

| Plan category                                              |     | Number of securities to be issued upon exercise of 
 outstanding options, warrants and rights           |         |     | Weighted- average exercise price of outstanding options, 
 warrants and rights                                      |      |     | Number of securities remaining available for future